Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. - Wikidata - awgldk - TriplyDB

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

http://www.wikidata.org/entity/Q36042091

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies BRCAness: finding the Achilles heel in ovarian cancer Trial watch - inhibiting PARP enzymes for anticancer therapy Role of Biomarkers in the Development of PARP Inhibitors DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer PARP inhibitors in the management of breast cancer: current data and future prospects DNA damage response and prostate cancer: defects, regulation and therapeutic implications Targeting triple-negative breast cancer: optimising therapeutic outcomes Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors MVP and vaults: a role in the radiation response The role of PARP in DNA repair and its therapeutic exploitation Advances in using PARP inhibitors to treat cancer The proteomic landscape of triple-negative breast cancer.Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors Fine tuning chemotherapy to match BRCA1 status Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.Therapeutic targeting of cancers with loss of PTEN function.Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.Integrated genomic analyses of ovarian carcinoma Understanding specific functions of PARP-2: new lessons for cancer therapy Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine Synthetic lethality in lung cancer and translation to clinical therapies Chemoresistance and targeted therapies in ovarian and endometrial cancers Drugging the addict: non-oncogene addiction as a target for cancer therapy PARP expression in germ cell tumours Novel non-AR therapeutic targets in castrate resistant prostate cancer An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma PARP inhibitor treatment in ovarian and breast cancer PARP inhibition: PARP1 and beyond Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.PARP inhibitors: its role in treatment of cancer.Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia Genome-wide transcriptome profiling of homologous recombination DNA repair.PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis.The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

P2860

Q21129302-87620755-807D-4797-93E8-37F1D0AE4B22 Q24630872-6DD52A36-71BC-495E-B924-0B7C9B2E25AE Q26745673-BA8AB859-1825-490D-A6FD-6A94AC1215AB Q26753159-97BF1A29-D399-4CD7-A2E0-14F75C33BD47 Q26776513-7D41381A-ED47-415A-AEBB-6CE52DEE0080 Q26783551-5FE2CA9D-3373-4168-BBBB-8D2FDC5010C1 Q26798352-AB6F5862-44B3-4755-87A1-08E9F8253CA2 Q26829155-C827F113-B424-47AC-97A2-DA47DF8947DF Q26850892-6719A043-CA47-4828-98F0-1AA776E5CD8F Q26851765-A47E4409-9EEC-45D9-BBD0-BD0A83ADFE00 Q26852274-9869C572-78DD-440E-891D-99F9B944E0CB Q26865123-7D59041F-88D3-40B2-A0FF-0B5203AAA7A3 Q27002399-93D964AE-909D-4B03-A14F-BBE221506D36 Q27003972-F0E741B7-DDED-4F05-B886-4774FC923411 Q27320721-91D16307-E58E-48C4-B548-A89DFC46EF34 Q27684311-9B4F94BD-D9E0-4D56-B9B4-285F919BD52C Q27694529-FB4F8210-A841-450E-B699-E8C5A40A0716 Q27852678-CADF4095-7234-4523-864A-4B07440D3787 Q27852764-46E4591C-427B-4805-89B7-28901D3BB3A0 Q27853007-68DF4718-0936-4F0C-8AEF-6DB8634E0E09 Q27860518-14727397-C768-47A5-A8DD-C43654631A33 Q28067486-FE600E5D-86F5-49CB-9DAD-F0242784DD2C Q28071541-91C1581A-5B4D-473B-84CC-F341A60F01D7 Q28072204-137BEC5A-A572-42DC-93B5-3FB071F3ABC2 Q28072904-76F8A500-08BD-47C4-8C2A-67B910574E62 Q28073246-0099A92E-603C-430E-B2D5-C65865168F0B Q28079559-29DB59CB-393C-4835-B9B0-6911C25A744E Q28287131-83AE1B77-FFA0-46D5-9860-C0E06BB04D64 Q28383663-5488A085-BD09-49F6-BE63-B56B6FB5D280 Q28485395-D5EF2EAF-67CF-4A05-858C-0A91AB4E1CB7 Q28550512-B75F12F2-2EC6-4B69-BB27-FCBC27598882 Q28741688-297748EA-CD77-4BF1-8326-9FE05670EA0F Q29619617-5C90464E-37EC-4C73-9670-5A766DE3E04F Q33557916-185BFC0D-6376-404D-B4C2-AAC3DC62442B Q33579740-97FCD875-B2FD-42FE-9C75-85AB07F883EC Q33584594-C283A6BA-FE37-4E52-8E8E-9CF9756B81CD Q33598112-1EDD059A-AEA5-4096-8658-748C006C36ED Q33599105-4332EC53-E4AC-44A9-BB43-FB13620DB88C Q33618536-4B174680-3293-4340-BD4B-E3C71FE9AA26 Q33618910-B8DE5794-0A56-422F-8DAE-01A3435236C8

P2860

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

http://www.wikidata.org/entity/Q36042091

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@ast

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@en

type

label

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@ast

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@en

prefLabel

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@ast

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@en

P1433

Q36042091-C5AA67EE-2CBB-489F-B2DB-B0D330CE631B

P1476

Q36042091-7D0ABA61-9E4C-4709-9EA5-A0F705C34E5F

P2093

Q36042091-082C8F78-8DEC-4589-A000-2C944FD8553A

Q36042091-2BE357E8-6F19-42EB-8C9D-471C8BBD0232

Q36042091-950175D2-07EC-4D44-9D98-7AE658867FF8

Q36042091-B077E3F5-A6EF-4128-9C73-C091A2F4101F

Q36042091-BB45F82B-987B-4C23-8534-AF7F84EEC5CF

Q36042091-BF8E151B-6E95-4E85-87F7-9A0FCBB1DB2C

Q36042091-E2CBB6FB-8807-4C7C-B679-75BE179E9BBC

P2860

Q36042091-08415991-BE97-4FFC-A2A5-2CFCF3C32F6A

Q36042091-0D3BF05B-8376-4803-A4DA-68059751378D

Q36042091-1207B8F1-7965-4289-BC86-E0F8EA6F8575

Q36042091-1D34E9DE-69B8-40C4-9E13-55494E14CDF5

Q36042091-43B03788-1E7D-4B21-B87E-C580F369EB27

Q36042091-4B21DD31-6268-4CF4-8EC7-617B9906D1EC

Q36042091-4CF40A98-05DA-476D-826E-EECDDFF04E7A

Q36042091-4DE80EDD-D1F6-49B8-87B5-56F70D493C46

Q36042091-79FCC845-8FD4-4722-AE30-0E7E73ABA519

Q36042091-7FBCE2F4-13F6-499B-88FF-66479406FFE1

P304

Q36042091-1ADF9D4B-43B1-48A4-85B1-1B4D0A593502

P31

Q36042091-B13549C3-CF56-4B38-A372-1FD25811B301

P356

Q36042091-963E7D98-CDF2-49E8-B179-8BE6CDEC02ED

P433

Q36042091-FC491FB6-233A-4F26-86B9-DDD3882496CC

P478

Q36042091-353DB54C-CE47-43DD-B18C-1A120BEB2F84

P50

Q36042091-05880E5A-3091-441D-B1B4-039A1288FECC

Q36042091-8A2229BD-7070-4255-91D6-00601809B71D

P577

Q36042091-D00F5462-F712-46D3-99CC-5C3B63AFC820

P5875

Q36042091-E435F60C-7566-4829-BC1F-9E8686A32D64

P698

Q36042091-12A8C415-EEDC-4DFD-977B-153FB70B8B3D

P932

Q36042091-F925C71B-959A-48B7-A8E6-46866754D859

P356

P1433

EMBO Molecular Medicine

P1476

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

@en

P2093

Afshan McCarthy

http://www.w3.org/2001/XMLSchema#string

Ana M Mendes-Pereira

http://www.w3.org/2001/XMLSchema#string

Jessica R Taylor

http://www.w3.org/2001/XMLSchema#string

Jung-Sik Kim

http://www.w3.org/2001/XMLSchema#string

Rachel Brough

http://www.w3.org/2001/XMLSchema#string

Sarah A Martin

http://www.w3.org/2001/XMLSchema#string

Todd Waldman

http://www.w3.org/2001/XMLSchema#string

P2860

Ubiquitination regulates PTEN nuclear import and tumor suppression

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Molecular views of recombination proteins and their control

The concept of synthetic lethality in the context of anticancer therapy

Resistance to therapy caused by intragenic deletion in BRCA2

Essential role for nuclear PTEN in maintaining chromosomal integrity

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

P304

315-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.200900041

http://www.w3.org/2001/XMLSchema#string

P433

6-7

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J Lord

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40848599

http://www.w3.org/2001/XMLSchema#string

P698

20049735

http://www.w3.org/2001/XMLSchema#string

P932

3378149

http://www.w3.org/2001/XMLSchema#string